Lurbinectedin Mesothelioma, Phase Ii Trial Of Lurbinectedin In Progressive Mesothelioma Finalizes Its Patient Recruitment Salute H24

Systemic second and third line therapies for malignant pleural mesothelioma mpm result in a median progression free survival mpfs of 2 months and median overall survival mos of 6 9 months.

Wright law firm. Lurbinectedin data for the treatment of progressive malignant pleural mesothelioma will be presented in an oral session at the international congress to be held this month in barcelona. Data on new combinations of trabectedin for the treatment of soft tissue sarcoma ovarian cancer and different solid tumors will also be revealed. In early trials encouraging outcomes occurred in patients pts with.

Early studies suggest lurbinectedin might make a good second line treatment for small cell lung cancer. The combination showed promising activity in both cases with manageable toxicity. Doctors in japan and europe have been using lurbinectedin in combination with chemotherapy to treat inoperable ovarian cancer.

Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma mpm. The new study focused on lurbinectedin a drug that impacts cancer cells at the dna level. Listing a study does not mean it has been evaluated by the us.

Results of the phase ii trial for lurbinectedin zepsyre as a single agent in the treatment of progressive malignant pleural mesothelioma mpm were presented at the recent european society of medical oncology esmo congress 2019biopharmaceutical company pharmamar developer of the innovative investigational compound has already received approval for the filing of an accelerated new. It has already been tested as monotherapy or in combination with chemotherapy in several phase i iii trials in different tumor entities including small. Proffered paper 2 non metastatic nsclc and other thoracic malignancies mesothelioma and thymic carcinoma 1316 sakk 1716.

A multi center single arm phase ii trial. Mesothelioma patients who fail after first line therapy have few options. Metaxas was a part of earlier research that detailed the effectiveness of lurbinectedin when used with cisplatin with two mesothelioma patients in switzerland.

A multicenter international single arm phase ii trial of lurbinectedin in progressive malignant pleural mesothelioma mpm has been presented at esmo. Lurbinectedin pm01183 is a novel compound which covalently binds to the dna minor groove inducing double strand breaks as well as selectively reducing the tumor associated macrophages. Herein we report two patient cases with mesothelioma who received second line chemotherapy with the combination of cisplatin and the novel compound lurbinectedin.

Lurbinectedin binds to the dna of the regulatory region while inhibiting tumour associated macrophage transcription. Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma.